Cited 115 times in
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 임선민 | - |
dc.date.accessioned | 2022-11-24T00:45:05Z | - |
dc.date.available | 2022-11-24T00:45:05Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190935 | - |
dc.description.abstract | Single-agent osimertinib is the standard of care for the first-line treatment of advancedEGFR+ NSCLC and remained the only marketed third-generation EGFR tyrosine kinase inhibitor (TKI) until March 2020 when almonertinib (HS-10296) was approved in the People's Republic of China for the treatment of advanced EGFR T790M+ NSCLC based on a phase 2 expansion study of a phase 1/2 trial. In this review, we profiled many of the third-generation EGFR TKIs in late-stage clinical development (e.g., almonertinib, lazertinib, alflutinib1, rezivertinib, ASK120069, SH-1028, D-0316, and abivertinib) based on their interim results from phase 1 and phase 2 trials, and included the designs of the phase 3 trials and their chemical structures when publicly available. We also listed other third-generation EGFR TKIs in pipeline development based on the search of clinical trial registration websites. In addition, we summarized the results of clinical trials that previously reported third-generation EGFR TKIs (rociletinib, olmutinib, nazartinib, mavelertinib), including phase 3 results of rociletinib and naquotinib. We further profiled combination clinical trial design of the third-generation EGFR TKIs including FLAURA2 (NCT04035486), MARIPOSA (NCT04487080), ACROSS1 (NCT04500704), and ACROSS2 (NCT04500717) that if positive can potentially usher in the next standard of care for advanced EGFR+ NSCLC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | JOURNAL OF THORACIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Acrylamides | - |
dc.subject.MESH | Aniline Compounds | - |
dc.subject.MESH | China | - |
dc.subject.MESH | Clinical Trials, Phase I as Topic | - |
dc.subject.MESH | Clinical Trials, Phase II as Topic | - |
dc.subject.MESH | ErbB Receptors / genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Morpholines | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Protein Kinase Inhibitors* / therapeutic use | - |
dc.subject.MESH | Pyrazoles | - |
dc.subject.MESH | Pyrimidines | - |
dc.title | Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Misako Nagasaka | - |
dc.contributor.googleauthor | Viola W Zhu | - |
dc.contributor.googleauthor | Sun Min Lim | - |
dc.contributor.googleauthor | Michael Greco | - |
dc.contributor.googleauthor | Fengying Wu | - |
dc.contributor.googleauthor | Sai-Hong Ignatius Ou | - |
dc.identifier.doi | 10.1016/j.jtho.2020.11.028 | - |
dc.contributor.localId | A03369 | - |
dc.relation.journalcode | J01909 | - |
dc.identifier.eissn | 1556-1380 | - |
dc.identifier.pmid | 33338652 | - |
dc.subject.keyword | Alflutinib | - |
dc.subject.keyword | Almonertinib | - |
dc.subject.keyword | Furmonertinib | - |
dc.subject.keyword | Lazertinib | - |
dc.subject.keyword | Osimertinib | - |
dc.subject.keyword | Rezivertinib | - |
dc.subject.keyword | T790M | - |
dc.contributor.alternativeName | Lim, Sun Min | - |
dc.contributor.affiliatedAuthor | 임선민 | - |
dc.citation.volume | 16 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 740 | - |
dc.citation.endPage | 763 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THORACIC ONCOLOGY, Vol.16(5) : 740-763, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.